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a b s t r a c t
INTRODUCTION: Intraoperative identiﬁcation of tumors can be challenging. Near-infrared (NIR) ﬂuores-
cence imaging is an innovative technique that can assist in intraoperative identiﬁcation of tumors, which
may otherwise be undetectable.
PRESENTATION OF CASE: A 19-year-old patient with symptoms, normetanephrine levels and radiolog-
ical ﬁndings suspicious for a paraganglioma, a rare tumor arising from extra-adrenal chromafﬁn cells
within the sympathetic nervous system, is presented. Intraoperative NIR ﬂuorescence imaging using
intravenous administration of methylene blue (MB) assisted in intraoperative detection of the tumor,
and even identiﬁed a smaller second lesion, whichwas not identiﬁed during surgery by visual inspection.
DISCUSSION: Although the exact mechanism of MB accumulation in neuroendocrine tumors is unclear, it
is described in both preclinical and clinical studies.
CONCLUSION: In this report, we describe the ﬁrst case of intraoperative NIR ﬂuorescence imaging of a
paraganglioma using MB, which identiﬁed an otherwise undetectable lesion.
© 2014 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open
access article under the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
1. Introduction
Paragangliomas are rare tumors arising from extra-adrenal
chromafﬁn cells within the sympathetic nervous system [1–3].
They can be found anywhere from the neck to the pelvis in
the vicinity of sympathetic ganglions, and belong to the fam-
ily of neuroendocrine tumors. An incidence rate of 2–8 cases
per million is reported, and tumors can be either functional or
non-functional. When functional there can be production of cat-
echolamine, epinephrine, or norepinephrine.
The only curative treatment of paraganglioma is complete sur-
gical resection. To help localize all sites of disease, preoperative
identiﬁcation can be performed using different anatomical and
functional imaging modalities [4]. However, no speciﬁc imaging
modalities are available for the intraoperative identiﬁcation of
these tumors.
Near-infrared (NIR) ﬂuorescence imaging is a promising tech-
nique to assist in the intraoperative identiﬁcation of sentinel lymph
nodes, tumors, and vital structures [5]. Advantages of this optical
imaging technique include real-time imaging, high sensitivity, and
high resolution, with penetration depths several millimeters into
tissue.
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Methylene blue (MB) is a clinically available tracer, which can
be used at low dosage as a ﬂuorescent tracer during NIR ﬂuores-
cence imaging.Winer et al. [6] describe the successful identiﬁcation
of insulinomas, a pancreatic neuroendocrine tumor in transgenic
mice, and clinically, the intraoperative identiﬁcation of parathyroid
adenomas was described [7].
Based on these results, we explored the possibility to identify
paragangliomas during surgery, using NIR ﬂuorescence imaging
and MB.
2. Presentation of case
A 19-year-old female patient presented with complaints of
fainting, nausea, vomiting, headaches, excessive sweating, ﬂushing
attacks, hand tremors, and heart palpitations. She had a negative
family history for endocrine diseases or paragangliomas.While vol-
unteering to donate blood, her systolic blood pressure was found
to be 180mm Hg. After referral, physical examination revealed a
blood pressure of 180/110mm Hg on the left arm, 190/115mm Hg
on the right arm, but no other abnormalities. Laboratory evalua-
tion showed a normetanephrine level of 3227umol/mol creatinine
(norm. value 64–260) in the urine.
CT scan showed a 46×38mm retroperitoneal mass, just caudal
to the aortic bifurcation (Fig. 1). Cranial to this, a smaller lesion of
6mm was seen, which was characterized as a para-aortic lymph
node. MRI scan conﬁrmed the retroperitoneal mass just caudal to
http://dx.doi.org/10.1016/j.ijscr.2014.12.002
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Fig. 1. Preoperative imaging of paraganglioma: Preoperative CT, T2 weighed MRI
and MIBG scan of the paraganglioma (dashed circle), retroperitoneally located, just
caudal to the aortic bifurcation.
the aortic bifurcation,with features suspicious for a paraganglioma.
A slight encasement of the common iliac vein was seen. The cra-
nially located smaller lesion was not clearly identiﬁed by MRI.
A 123I-metaiodobenzylguanidine (MIBG) scanwas performed to
search for lesions located elsewhere in the body. Strong accumu-
lation of the tracer was seen in the lesion just caudal to the aortic
bifurcation, but no other uptake was seen (Fig. 1).
The patient was scheduled for resection. She was successfully
pretreated with doxazosine, a selective alpha1-receptor blocking
sympatholytic drug, metoprolol, a beta-receptor blocking sympa-
tholytic drug, and nifedipine, a dihydropyridine, in order to prevent
a hypertensive crisis during surgery.
2.1. Intraoperative NIR ﬂuorescence imaging
The current study was approved by theMedical Ethics Commit-
tee of the Leiden University Medical Center and was performed in
accordance with the clinical standards of the Helsinki Declaration
of 1975. Written informed consent was obtained.
During surgery, and directly after exposure of the lesion dis-
tal to the aortic bifurcation, MB was administered intravenously
(0.5mg/kg; 33mg in 3.3mL of water; 10mg/mL ﬁnal stock solu-
tion concentration) over 5min and NIR ﬂuorescence imaging was
performed using the Mini-FLARE image-guided surgery system as
described previously [8]. Directly after infusion, imaging was per-
formed at ﬁxed time points (0, 1, 2, 3, 4, 5, 15, 30 and 45min).
NIR ﬂuorescence imaging showed a strong, but patchy, ﬂuores-
cent signal corresponding to the suspected lesion (Fig. 2A, lesion
indicated by dashed circle). Moreover, the additional small lesion
that was only identiﬁed by CT but not by MRI or by visual inspec-
tion during surgery, was clearly identiﬁed using NIR ﬂuorescence
Fig. 2. Intraoperative and ex vivo NIR ﬂuorescence imaging of primary and metastatic paragangliomas: (A) Intraoperative NIR ﬂuorescence imaging of the surgical ﬁeld. A
bright, patchy ﬂuorescent signal was identiﬁed at the location of the tumor (dashed circle). A second, small, lesion located approximately 5 cm cranial to themain lesion, was
also identiﬁed using NIR ﬂuorescence imaging (arrow). (B) Ex vivo (T=45min) imaging of the resection specimens. Fluorescent signal was seen in the large (dashed circle)
and small lesion (arrow). A weaker ﬂuorescent intensity was seen than in vivo, because ﬂuorescent signal decreased over time during surgery. (C) Ex vivo imaging of the
bisected main lesion. Bright ﬂuorescent signal was seen throughout the paraganglioma (dashed circle).
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Fig. 3. Tumor-to-background ratio of resected lesions: Tumor-to-background ratio
of the largemain lesion and small second lesion over time after intravenous admin-
istration of MB.
imaging, located approximately 5 cm cranial to the main lesion
(indicated by arrow). This lesion was otherwise undetectable.
Already two minutes after administration, a tumor-to-background
ratio (TBR) of approximately 3.5 was reached for both lesions,
which slowly decreased over the next 30min (Fig. 3).
After en bloc resection of the 2 lesions, the specimen was sent
to pathology for further evaluation. After surgical treatment, symp-
toms disappeared and normetanephrine levels normalized.
No surgical complication or adverse reactions associated with
the use of MB or ﬂuorescence imaging were observed.
2.2. Ex vivo imaging of resected lesion and sliced specimen
Ex vivo imaging of the resected specimens was performed at
the Pathology department using the FLARE imaging system, which
was previously described [9]. Images showed aﬂuorescent signal in
both lesions (Fig. 2B).Of special note, the intensityof theﬂuorescent
signal decreased signiﬁcantly over time, so amuchweaker ﬂuores-
cence signal was measured during ex vivo imaging (i.e., T=45min
afterMB injection). Thepatchyﬂuorescent signal of themain tumor
was seen both in vivo and ex vivo. This was due to ﬁbrous con-
nective tissue lying over the paraganglioma. After bisection of the
resectedmain lesion, a clearﬂuorescent signalwas seen throughout
the tumor (Fig. 2C).
2.3. Histopathology
Macroscopically, a nodular lesion was seen, yellow to black on
cross section and surrounded by a thin capsule. The maximum
diameter was 65mm. Cranial from this lesion, a smaller lesion
of 12mm was seen, suspicious for a tumor-positive lymph node
(Fig. 2B). The excised tissue was ﬁxed in formalin, embedded in
parafﬁn and tissue slides were stainedwith hematoxylin and eosin
(HE). Immunohistochemical staining was also performed (Fig. 4).
Based on histopathological ﬁndings, both lesions were diagnosed
as paraganglioma with diameters of 65 and 12mm, respectively.
3. Discussion
Despite many preoperative imaging modalities, intraoperative
identiﬁcation and demarcation of paragangliomas can be chal-
lenging. Because complete surgical removal of the tumor is the
only curative treatment option, real-time intraoperative imaging
modalities which can assist in tumor identiﬁcation are desperately
needed. To the best of our knowledge, this is the ﬁrst report show-
ing the intraoperative identiﬁcation of paragangliomas using NIR
ﬂuorescence imaging and MB in a clinical setting.
In the presented patient, the main lesion just caudal to the aor-
tic bifurcation was clearly identiﬁed by CT, MRI, and MIBG-scan.
CT also showed a cranially located smaller lesion, which was not
identiﬁed by MRI or MIBG, and not recognized as a paraganglioma,
probably due to its small size and/or lack of adequate tracer photon
ﬂux from small tumors [3,10]. Importantly, intraoperative identiﬁ-
cation of all tumors is of paramount importance for the complete
surgical resection and thereby curative treatment. Although not
identiﬁed byMRI orMIBG, the second, smaller, lesionwas intensely
ﬂuorescent and was conﬁrmed histologically to be paraganglioma.
In daily practice, there still is a discrepancy between identiﬁcation
of lesions during preoperative imaging and intraoperative recog-
nition of these lesions, especially when they are smaller sized.
Intraoperative NIRF imaging could potentially overcome this gap.
The pharmacokinetics of MB in the observed lesions are consis-
tent with a perfusion effect, but not for a retention effect, because
TBR decreases rapidly over time after initially high values. This
makes the administration ofMB for intraoperative identiﬁcation of
paragangliomas very useful for the direct identiﬁcation of lesions,
and apparently local metastases or second primary tumors.
Although the exact mechanism of MB accumulation in tumors
andespeciallyneuroendocrine tumors ismainlyunclear, it hasbeen
described in several studies. Previous clinical studies show stain-
ing of neuroendocrine tumors and parathyroid adenomas using
MB as a visible dye using high concentrations [11–14] and with
NIR ﬂuorescence imaging using low-dose MB [7]. Also in breast
cancer, identiﬁcation of tumors by NIR ﬂuorescence imaging using
MB is described [15]. The mechanism behind this accumulation is
based on physicochemical similarities between MB and sestamibi,
a nuclear tracer used for MIBI-scans. Reports which describe the
identiﬁcation of paragangliomas using MIBI-scan are rare [16,17],
but strengthens the hypothesis that MB and sestamibi have a
comparable biodistribution. A better understanding of the exact
Fig. 4. Histopathological staining of resected lesions: hematoxylin and eosin, Laguesse, S100 and SDHB staining of the resected specimen.Microscopy showed a characteristic
pattern of cell nests. This pattern was accentuated by a reticulin stain. The cells had a moderate amount of eosinophilic cytoplasm and nuclei with ﬁnely clumped chromatin.
Dispersed throughout the lesion, hemorrhagic foci were seen. The second, small, cranially located lesion showed the same characteristics as the larger lesion, without the
presences of surrounding lymphoid tissue. Additional immunohistochemical staining for S100 showed the presence of sustentacular cells around the nests. SDHB staining
was not conclusive.
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mechanism would be of obvious clinical importance, since this
technique could potentially enhance patient cure rates.
4. Conclusion
In conclusion,wedescribe the successful use ofNIRﬂuorescence
imaging for the intraoperative identiﬁcation of a paraganglioma
using MB. This procedure is easy to perform and could result in
an increased number of complete resections in paraganglioma
surgery. In general, this technique could usher in a new era of
optical assistance in the detection of tumors during surgery.
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Key Learning Points
• NIRﬂuorescence imagingusingMBcanbeused for intraoperative
identiﬁcation of paragangliomas.
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• This technique could result in amore complete resection of para-
gangliomas.
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